• LAST PRICE
    33.1200
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    28.0000/ 1
  • Ask / Lots
    35.0000/ 1
  • Open / Previous Close
    0.0000 / 33.1200
  • Day Range
    ---
  • 52 Week Range
    Low 18.6900
    High 46.4600
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 34.66
TimeVolumeRGNX
09:32 ET499134.45
09:39 ET10034.15
09:43 ET20034.51
09:45 ET15834.6113
09:50 ET33634.35
09:52 ET10034.24
09:57 ET10034.48
09:59 ET74334.64
10:01 ET60034.47
10:06 ET20034.39
10:12 ET30034.35
10:14 ET40034.27
10:15 ET20034.38
10:17 ET20034.32
10:19 ET30034.4
10:21 ET48734.51
10:26 ET34434.458
10:28 ET40034.61
10:30 ET59434.43
10:32 ET69734.425
10:35 ET59934.72
10:37 ET10034.63
10:39 ET10034.68
10:42 ET10034.81
10:44 ET40034.7
10:46 ET10034.7
10:48 ET130034.51
10:51 ET27534.53
10:53 ET30034.71
10:55 ET20034.57
10:57 ET10034.51
11:02 ET20034.68
11:06 ET20034.565
11:08 ET40034.38
11:09 ET23034.34
11:11 ET20034.235
11:13 ET10034.3
11:15 ET79634.22
11:20 ET30034.2
11:22 ET30034.24
11:24 ET50034.19
11:26 ET20034.07
11:27 ET51634.1
11:29 ET20033.94
11:31 ET20033.91
11:33 ET50033.95
11:36 ET30033.88
11:38 ET50833.84
11:40 ET20033.81
11:42 ET40033.75
11:44 ET10033.74
11:45 ET50033.65
11:47 ET50033.5
11:49 ET51133.43
11:51 ET112333.4
11:54 ET95033.516
11:56 ET60033.65
11:58 ET10033.65
12:00 ET70033.55
12:02 ET40033.46
12:05 ET10033.56
12:07 ET10033.58
12:09 ET40033.66
12:12 ET20033.56
12:14 ET20033.53
12:16 ET60033.43
12:18 ET10033.64
12:23 ET20033.755
12:27 ET20033.68
12:34 ET10033.85
12:36 ET10033.92
12:38 ET10033.995
12:39 ET52133.92
12:48 ET20033.88
12:52 ET219933.935
12:54 ET30033.87
12:57 ET245033.87
12:59 ET395733.79
01:01 ET100433.81
01:03 ET20033.7848
01:06 ET20033.69
01:10 ET20033.625
01:14 ET180033.67
01:17 ET23733.725
01:19 ET20033.8
01:21 ET10033.725
01:24 ET60033.71
01:26 ET53433.71
01:28 ET30033.7
01:32 ET30033.67
01:33 ET10033.59
01:35 ET30033.5
01:37 ET130033.49
01:39 ET10033.47
01:42 ET50033.5
01:44 ET20033.52
01:46 ET10033.51
01:53 ET21633.48
01:57 ET30033.42
02:06 ET20033.35
02:08 ET50033.39
02:09 ET30033.31
02:11 ET1680033.3
02:13 ET60033.42
02:24 ET20033.56
02:26 ET5030033.67
02:27 ET40033.71
02:29 ET70033.7
02:31 ET54233.65
02:36 ET20033.55
02:38 ET30033.655
02:40 ET20033.605
02:42 ET30033.545
02:45 ET20033.43
02:47 ET70133.35
02:49 ET188133.47
02:51 ET20033.43
02:54 ET20033.4
02:56 ET20033.33
02:58 ET90033.385
03:00 ET20033.41
03:03 ET50033.345
03:07 ET20033.29
03:09 ET117033.21
03:12 ET20033.12
03:14 ET20033.11
03:16 ET20033.1
03:18 ET110033.155
03:21 ET124033.065
03:23 ET40033.06
03:25 ET40033.03
03:27 ET118333.04
03:30 ET110033.193
03:32 ET334433.03
03:36 ET10033.025
03:38 ET128933
03:39 ET72132.93
03:41 ET75032.96
03:43 ET140032.93
03:45 ET40032.9
03:48 ET180032.79
03:50 ET126832.87
03:52 ET120032.955
03:54 ET210033.1
03:56 ET173333.13
03:57 ET1022333.04
03:59 ET13179833.12
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesRGNX
Regenxbio Inc
1.5B
25.4x
---
United StatesPIII
P3 Health Partners Inc
1.2B
-13.4x
---
United StatesIRWD
Ironwood Pharmaceuticals Inc
1.8B
11.6x
---
United StatesRCUS
Arcus Biosciences Inc
1.9B
175.3x
---
United StatesQURE
Uniqure NV
912.6M
-8.0x
---
United StatesDVAX
Dynavax Technologies Corp
2.2B
12.4x
---
As of 2022-08-12

Company Information

REGENXBIO Inc. is a clinical-stage biotechnology company focused on providing curative potential of gene therapy. The Company's investigational gene therapies are designed to deliver functional genes to address genetic defects in cells. Its investigational AAV Therapeutics include: RGX-314, which is developing in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases characterized by loss of vision; RGX-202, which is developing to treat Duchenne muscular dystrophy (Duchenne), one of the most common fatal genetic disorders affecting children; RGX-121, RGX-111 and RGX-181, which is developing to treat Mucopolysaccharidosis type II (MPS II), Mucopolysaccharidosis type I (MPS I), and late infantile neuronal ceroid lipofuscinosis type II (CLN2 disease)., and RGX-381, which is developing to treat the ocular manifestations of CLN2 disease.

Contact Information

Headquarters
9804 Medical Center DriveROCKVILLE, MD, United States 20850
Phone
240-552-8181
Fax
302-655-5049

Executives

Chairman of the Board
Allan Fox
President, Chief Executive Officer, Director
Kenneth Mills
Chief Financial Officer, Executive Vice President
Vittal Vasista
Executive Vice President, Chief Operations, Technology Officer
Curran Simpson
Executive Vice President, Chief Scientific Officer
Olivier Danos

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.5B
Revenue (TTM)
$484.3M
Shares Outstanding
43.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.09
EPS
$1.30
Book Value
$17.84
P/E Ratio
25.4x
Price/Sales (TTM)
3.1
Price/Cash Flow (TTM)
14.8x
Operating Margin
25.23%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.